Bristol-Myers Squibb Company
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BMY.MX | LLY | ABBV | GIS.DE | BIIB | AMG.F | |
|---|---|---|---|---|---|---|
| Market cap | 2.43T | 1.26T | 521.00B | 192.80B | 37.61B | 229.09B |
| P/E (TTM) | 15.0 | 46.0 | 50.7 | — | 110.2 | 28.5 |
| Forward P/E | — | 28.3 | 18.2 | — | 15.6 | — |
| Price/book | 5.6 | 31.4 | -113.7 | 16.6 | 2.0 | 17.9 |
| Dividend yield | 3.98% | 0.49% | 2.35% | 1.93% | — | 2.16% |
| 1-year change | +38.78% | +51.26% | +34.60% | +42.44% | +62.35% | +53.62% |
| Today | +0.52% | +0.61% | +3.09% | +0.57% | +2.22% | −0.20% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All BMY.MX news ›What Could Derail Bristol Myers Squibb Stock?
Bristol Myers Squibb (BMY) stock returned 42.9% over the past year, compared to 11.5% for the S&P 500. If you own the stock, you want to know what could take some of that gain back, and management has already pointed to pressure on its…
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing openPR.com Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma,…
Bausch Health Cos (NYSE:BHC) & Bristol Myers Squibb (NYSE:BMY) Head-To-Head Comparison
Posted by Sarita Garza on Nov 4th, 2026 Bristol Myers Squibb (NYSE:BMY – Get Free Report) and Bausch Health Cos (NYSE:BHC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies…
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Danish biotech Genmab has seen its shares double in three months after a string of major cancer drug trial successes, giving fresh momentum to its push to take greater control of the medicines it develops and sells. Shares in the roughly…
Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, AstraZeneca, Sanofi, Amgen
Albany New York November 03 2026 As per DelveInsight s assessment globally Cutaneous Lupus Erythematosus pipeline constitutes 8 key companies continuously working towards developing 10 Cutaneous Lupus Erythematosus treatment therapies…
Tempus AI, Inc. Enters Into Multi-Year Agreement With Bristol Myers Squibb To License Multimodal Oncology Data
Tempus AI, Inc. announced a multi-year agreement with Bristol Myers Squibb, under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight... announced a multi-year agreement with…
Total common shares outstanding of Bristol-Myers Squibb Company Shs Canadian Depositary Receipt Repr Shs Reg S – FWB:BRM0
Total common shares outstanding of Bristol-Myers Squibb Company Shs Canadian Depositary Receipt Repr Shs Reg TradingView Bristol-Myers Squibb Company Shs Canadian Depositary Receipt Repr Shs Reg S Total common shares outstanding of…
Bristol Myers Squibb (NYSE:BMY) Stock Price Breaks Above 50 Day Moving Average on Analyst Downgrade
Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) shares crossed above its fifty day moving average during trading on Monday after The Goldman Sachs Group upgraded the stock from a hold rating to a strong-buy rating. The stock has…
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown. Is your portfolio ready for the shifting landscape of modern medicine?…
Why analysts aren’t covering your biotech company
Empower your organization with a suite of forecasting tools designed to enhance decision-making and refine your commercial strategy. Enhance asset management with powerful tools that enable data-driven decisions and optimize your…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com25
- fool.com18
- marketbeat.com17
- theglobeandmail.com16
- themarketsdaily.com12
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.